Globally Recognized Scientific Policy and Genomics Expert Genya Dana, Ph.D. Joins Avellino as Global Head of Health Policy

MENLO PARK, Calif.–()–Avellino Lab USA, Inc. (Avellino) today announced Genya Dana, Ph.D., as Global Head of Health Policy for the company. Genya comes to Avellino from the World Economic Forum (the Forum), where she served as its Head of Healthcare. There, she led an international team focused on cultivating multi-stakeholder partnerships across health and healthcare, including initiatives in precision medicine, women and girls’ health, health equity, and pandemic forecasting and response.

“On behalf of the Board of Directors and myself, we would like to welcome Genya to Avellino and are thrilled to add her exceptional talents and global scientific experience to the company,” says Avellino Founder and Chairman Gene Lee. “We could not have asked for a better professional to lead our policy and partnership work to expand our reach in providing precision medicine solutions globally.”

“It is an honor to welcome Genya to Avellino. I am extremely confident in her ability to help lead our next chapter of growth as we continue to develop our powerful data-centric diagnostic and therapeutic solutions in healthcare,” says Avellino CEO Jon Robson. “Genomic data is the next frontier of developing novel approaches to disease, and Genya’s experience and skill in healthcare policy and partnerships will help the company develop a cross-border genetic data approach that can accelerate outcomes among a wide range of scientific and healthcare institutions.”

“I have dedicated my career to enabling innovative science and technology that improves lives, the economy and the environment. It is extremely gratifying to join a company such as Avellino that shares the same passion as I do for harnessing the genomic revolution and making applications accessible worldwide,” says Ms. Dana. “Enabling advances in health and healthcare requires collaboration, creativity, cutting-edge science and agile policies, and I am excited to bring my expertise in these areas to one of the most exciting biotechnology companies in the US.”

In addition to her previous role at the Forum, Genya also served as its Head of Precision Medicine and Head of Healthcare Initiatives. Prior to this, she held a number of high-profile roles at the US Department of State, which included serving as a negotiator in the United Nations on science, technology and innovation agreements, and leading the development of the US position on synthetic biology and emerging biotechnologies. She has also held a number of community leadership appointments, including serving on the Board of Directors for Innovations in Healthcare; the Board for Responsible Conduct at the International Genetically Engineered Machines (iGEM) Foundation; and the Board of Operations for Ending Workplace Tuberculosis.

Genya received a Ph.D. in Biotechnology and Risk Assessment and a Master of Science in Science, Technology, and Environmental Policy from the University of Minnesota and a Bachelor of Science in Molecular Biology from Emory University.

About Avellino

Avellino Lab USA, Inc. is a global leader in genetic molecular diagnostics at the forefront of precision medicine for eyecare. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. The company also developed the Avellino SARS-CoV-2 RT-PCR diagnostic test (AvellinoCoV2) to aid in COVID-19 pandemic testing efforts in the US and was the first private, independent company in the US to receive an EUA for its COVID-19 test. Avellino is headquartered in Menlo Park, California, with operations in Korea, Japan, and UK with future plans for further expansion in both Asia and Europe.

To learn more about Avellino, visit


Recent Articles

Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.